# Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI

**Authors:** Jack O’Shaughnessy, Arina Martynchyk, Sze Ting Lee, Geoff Chong, Shivam Agrawal, Maciej Tatarczuch, Nariza Alysa Azryn, Gareth P Gregory, Leonid Churilov, Michael Wang, Colm Keane, Eliza A Hawkes

PMC · DOI: 10.1093/noajnl/vdaf090 · Neuro-Oncology Advances · 2025-05-05

## TL;DR

This study shows that measuring tumor volume changes in 3D using MRI can better predict outcomes for patients with brain lymphoma than traditional 2D methods.

## Contribution

The study introduces 3D volume reduction as a novel and more accurate method for assessing treatment response in PCNSL.

## Key findings

- A 3D volume reduction of ≥58% at interim and end-of-treatment was linked to significantly better survival outcomes.
- Standard 2D complete response did not show better survival than partial response in PCNSL patients.
- 3D volume calculations may provide a more sensitive response assessment method for PCNSL.

## Abstract

Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably predicted. The International PCNSL Collaborative Group developed standardized response assessment utilizing 2-dimensional (2D) Magnetic Resonance Imaging (MRI) tumor measurements. Considerable challenges of this approach exist due to many reasons. Recent glioblastoma and PCNSL data demonstrated that radiological assessment of baseline 3-dimensional volume (3DV) as well as 3DV reduction (3DVR) may be a sensitive prognostic parameter.

Our multicentre retrospective study evaluated semiautomated 3DV in 74 PNCSL patients undergoing curative-intent chemoimmunotherapy.

Baseline tumor 3DV was not associated with survival. Compared to 3DVR < 58% (ROC-determined threshold based on our cohort), both interim and End-of-Treatment (EOT) 3DVR ≥ 58% in responding patients were associated with statistically significant prolonged 2-year progression-free survival (PFS) (interim: 73% (95%CI 57-83) versus 22% (95%CI 3-51), P = 0.005; EOT: 75% (95%CI 59-85) versus 0%, P = 0.002) and 2-year OS (interim: 83% (95%CI 68-91) versus 38% (95%CI 9-67), P = 0.02; EOT: 86% (95%CI 70-93) versus 0%, P = 0.0002). However, no significant differences in PFS or OS were observed in patients achieving standard 2D complete response (CR) compared to partial response (PR).

Although PCNSL tumor 3DV at baseline is not associated with survival outcomes, 3DVR of ≥58% in interim and EOT confers superior PFS and OS. Whereas, no difference in survival was observed using standard 2D CR versus PR response assessment at the same time-points. 3DV calculations may offer a sensitive method of response assessment for PCNSL. We are currently validating this in clinical trials.

## Linked entities

- **Diseases:** Primary central nervous system lymphoma (MONDO:0002571), PCNSL (MONDO:0002571)

## Full-text entities

- **Diseases:** PCNSL (MESH:D008223), glioblastoma (MESH:D005909), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12202003/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12202003/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12202003/full.md

---
Source: https://tomesphere.com/paper/PMC12202003